Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer

Thumbnail Image

Files

31-Biodistribution and dosimetry.pdf (2.53 MB)

Date

2025-02-03

Document type

journal article

Collections

Investigación
Total downloads14
Total views3
Bibliographic managers

Authors

Ritt, Philipp, Fernandez, Rene, Soza-Ried, Cristian, Nicolai, Heinz, Amaral, Horacio, Krieger, Korbinian, Mapanao, Ana Katrina, Rotger, Amanda, Zhernosekov, Konstantin, Schibli, Roger, Müller, Cristina, Kramer, Vasko

Publisher

Springer Science and Business Media LLC

URI

https://repositorio.udla.cl/handle/udla/1875

DOI

https://doi.org/10.1007/s00259-025-07102-8

Keywords

[Lu-177]Lu-SibuDAB, Radiopharmaceutical therapy, Albumin binder, MCRPC, Prostate cancer, Dosimetry

Citation

European Journal of Nuclear Medicine and Molecular Imaging, 52(7), 2431-2443. https://doi.org/10.1007/s00259-025-07102-8

Abstract

Purpose Several prostate-specific membrane antigen (PSMA) radiopharmaceuticals have been used for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). In an attempt to improve th...

Endorsement

Review

Supplemented By

Referenced By

Creative Commons license

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwised noted, this item's license is described as Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Usage statistics
01345
Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26